Broluzumab Biosimilars Market

Brolucizumab is a humanized single-chain antibody fragment for the treatment of neovascular (wet) age-related macular degeneration (AMD). The most common side effects are reduced visual acuity, cataract (clouding of the lens in the eye), conjunctival haemorrhage (bleeding at the front of the eye) and vitreous floaters (spots in the vision). The most serious side effects are blindness, endophthalmitis (an infection inside the eye), retinal artery occlusion (blockage of the artery in the retina) and retinal detachment (separation of the retina from the back of the eye). Brolucizumab was designed to attach to and block a substance called vascular endothelial growth factor A (VEGF-A). VEGF-A is a protein that makes blood vessels grow and leak fluid and blood, damaging the macula. By blocking VEGF-A, brolucizumab reduces the growth of the blood vessels and controls the leakage and swelling.

Broluzumab Biosimilars Market contains market size and forecasts of Broluzumab Biosimilars in global, including the following market information:

Global Broluzumab Biosimilars Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global Broluzumab Biosimilars Market Sales, 2017-2022, 2023-2028, (K Units)

Global top five Broluzumab Biosimilars companies in 2021 (%)

The global Broluzumab Biosimilars market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Beovu Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Broluzumab Biosimilars include Novartis, Genentech, Roche, Pfizer, Sartorius, Eli Lilly, Bayer, Amgen and PlantForm, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Broluzumab Biosimilars manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Broluzumab Biosimilars Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Broluzumab Biosimilars Market Segment Percentages, by Type, 2021 (%)

Beovu

Vsiqq

Others

Global Broluzumab Biosimilars Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Broluzumab Biosimilars Market Segment Percentages, by Application, 2021 (%)

ARMD

Kaposi Sarcoma

Glioblastoma

Global Broluzumab Biosimilars Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Broluzumab Biosimilars Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Broluzumab Biosimilars revenues in global market, 2017-2022 (Estimated), ($ millions)

Key companies Broluzumab Biosimilars revenues share in global market, 2021 (%)

Key companies Broluzumab Biosimilars sales in global market, 2017-2022 (Estimated), (K Units)

Key companies Broluzumab Biosimilars sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Novartis

Genentech

Roche

Pfizer

Sartorius

Eli Lilly

Bayer

Amgen

PlantForm

PharmaPraxis

Samsung Bioepis

Centus

Cadila Pharmaceuticals

Dr Reddy's

Aurobindo Pharma

Biocad

MAbxience

Hetero

Biocon

Kirin Biologics

Mylan

BeiGene

Innovent

Qilu Pharmaceutical

Hengrui Pharmaceuticals

Hisun Pharmaceutical

TOT BIOPHARM

Luye Pharmaceutical

Henlius